Teva Pharmaceutical Industries Ltd (TEVA)

35.38
NYSE : Health Care
Prev Close 35.82
Day Low/High 35.27 / 35.91
52 Wk Low/High 31.90 / 59.34
Avg Volume 11.20M
Exchange NYSE
Shares Outstanding 1.01B
Market Cap 36.36B
EPS 0.10
P/E Ratio 6.97
Div & Yield 1.36 (3.80%)

Latest News

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Closing Bell: Apple Rallies to New Highs; U.S. Stocks End at Fresh Records for Day Three

Closing Bell: Apple Rallies to New Highs; U.S. Stocks End at Fresh Records for Day Three

Wall Street rallies to new records as leftover goodwill from Friday's rally pushes stocks to new heights.

Dow, S&P 500 and Nasdaq Score New Records for Third Straight Day

Dow, S&P 500 and Nasdaq Score New Records for Third Straight Day

The good vibes that carried Wall Street to new records last week lingered on into Monday's session.

Stocks Extend Gains, on Track to Close at Records for Third Day in Row

Stocks Extend Gains, on Track to Close at Records for Third Day in Row

The Dow Jones Industrial Average led Wall Street's gains on Monday on leftover goodwill from last week's Trump-inspired rally.

How to Trade Monday's Most Active Stocks: BofA, Vale, Zeltiq, Teva and More

How to Trade Monday's Most Active Stocks: BofA, Vale, Zeltiq, Teva and More

Here's how to trade seven of the most active names on the market.

Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

Allergan is buying body-sculptor Zeltiq. CEO Brent Saunders deems it to be the Botox of 10 years ago and he expects the deal to be immediately accretive.

Stocks Trade Above Record Closes, Apple Nears All-Time High

Stocks Trade Above Record Closes, Apple Nears All-Time High

Stocks edge higher on Monday as good vibes from Friday's record-breaking rally are sustained through the weekend.

Teva Claws Its Way Back With Earnings, Revenue Beat

Teva Claws Its Way Back With Earnings, Revenue Beat

The company had been free falling after CEO Erez Vigodman stepped down last week.

Market Recon: The Foundation Is Laid to Support This Rally

Market Recon: The Foundation Is Laid to Support This Rally

That support could become necessary should the blooming flower of tax reform come with a couple of thorns attached.

Teva Reports Full Year And Fourth Quarter 2016 Financial Results

Teva Reports Full Year And Fourth Quarter 2016 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the year and the quarter ended December 31, 2016.

Disney, Procter & Gamble and General Motors: Jim Cramer's Views

Disney, Procter & Gamble and General Motors: Jim Cramer's Views

Cramer shares his views about Disney, the most de-risked entertainment company ever, and wonders why, if Trump is so bad for stocks, there's no correction yet.

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Investors should keep an eye on interest rates and oil, but remember next week is still a week of big earnings reports, says Jim Cramer.

Teva Shares Decline After Company's CEO Exits

Teva Shares Decline After Company's CEO Exits

Teva's rich dividend yield may be too good to continue.

Dow Holds Gains, Nasdaq Scores New Record as Energy Shares Lag

Dow Holds Gains, Nasdaq Scores New Record as Energy Shares Lag

The Dow holds onto gains as oil prices fall and energy shares slide.

Cramer: If Trump Is So Bad for Stocks, Where's the Correction?

Cramer: If Trump Is So Bad for Stocks, Where's the Correction?

Yes, he's unpredictable, but is that a reason to sell?

Dow Remains Higher, S&P Slips as Oil Prices Drop, Energy Shares Lag

Dow Remains Higher, S&P Slips as Oil Prices Drop, Energy Shares Lag

Stocks lose steam Tuesday as oil prices fall and energy shares slide.

Despite Settling Decade-Long Suit, Mylan Shares Fall

Despite Settling Decade-Long Suit, Mylan Shares Fall

Mylan settled a pay-for-delay lawsuit over its narcolepsy drug, but its share prices are falling.

JIm Cramer: Investors Should Be Cautious With Teva Pharmaceutical

JIm Cramer: Investors Should Be Cautious With Teva Pharmaceutical

Jim Cramer discusses why investors should be cautious after Teva Pharmaceutical's CEO left the company.

Teva Pharmaceuticals CEO Steps Down After a Series of Missteps

Teva Pharmaceuticals CEO Steps Down After a Series of Missteps

The CEO of Teva Pharmaceuticals has left the company, which has faced a series of challenges.

Teva Searches for a New CEO

Teva Searches for a New CEO

The Jerusalem-based pharmaceutical company named Dr. Yitzhak Peterburg as interim CEO after Erez Vigodman stepped down following a mutual agreement with the board.

Teva Appoints Dr. Yitzhak Peterburg As Interim Chief Executive Officer, Succeeding Erez Vigodman

Teva Appoints Dr. Yitzhak Peterburg As Interim Chief Executive Officer, Succeeding Erez Vigodman

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that Dr.

Stocks Investors Are Buying and Sell This Year

Stocks Investors Are Buying and Sell This Year

For all the trepidation over a Trump administration, retail investors stayed squarely on the bullish side to start the year.

California Sues Teva, Allergan for Allegedly Blocking Generic Competition to Lidoderm

California Sues Teva, Allergan for Allegedly Blocking Generic Competition to Lidoderm

Civil suit claims units of drugmakers Teva and Allergan had a "pay-for-delay" deal on lidocaine patches.

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.

Teva Confirms Generic Victoza® Patent Challenge In The United States

Teva Confirms Generic Victoza® Patent Challenge In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that it has filed an abbreviated new drug application (ANDA) with the U.

Teva To Report Fourth Quarter 2016 Financial Results On February 13, 2017

Teva To Report Fourth Quarter 2016 Financial Results On February 13, 2017

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fourth quarter 2016 financial results on Monday, February 13, 2017 at 7:00 a.

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan's shares rose after Teva's claims of patent infringement were rejected, despite the announcement that the FTC is investigating the drugmaker for antitrust violations.